Published in Law and Health Weekly, January 14th, 2006
Under the terms of the agreement, shareholders of Abgenix will receive $22.50 in cash per common share.
The acquisition of Abgenix provides Amgen with full ownership of one of its most important advanced pipeline products, panitumumab. Working closely with Abgenix under a codevelopment agreement that Amgen assumed as a result of its acquisition of Immunex Corp. in 2002, Amgen has led the development and commercialization strategy for panitumumab.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly